Carcinoma, Ovarian Epithelial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The analysis also showed a substantial difference in the profile of genes contributing to either BC or OC risk, including genes specifically associated with a high risk of OC but not BC (e.g., RAD51C, and RAD51D).
|
30733081 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Significant associations with OC were observed in <i>BRCA1, BRCA2, RAD51C</i> and <i>RAD51D.</i> Other homologous recombination genes, <i>BARD1, NBN,</i> and <i>PALB2,</i> were not significantly associated with OC.
|
31341520 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Population-based BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing can prevent 1.86%/1.91% of BC and 3.2%/4.88% of OC in UK/US women: 657/655 OC cases and 2420/2386 BC cases prevented per million.
|
29361001 |
2018 |
Carcinoma, Ovarian Epithelial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece.
|
30111881 |
2018 |
Carcinoma, Ovarian Epithelial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
RAD51D is a key player in DNA repair by homologous recombination (HR), and <i>RAD51D</i> truncating variant carriers have an increased risk for ovarian cancer.
|
28646019 |
2017 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
RAD51 paralogs (RAD51B, RAD51C, RAD51D, XRCC2, and XRCC3) have recently been involved in breast and ovarian cancer predisposition: RAD51B, RAD51C, and RAD51D in ovarian cancer, RAD51B and XRCC2 in breast cancer.
|
29255180 |
2017 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two components of the complex, RAD51C and RAD51D, increase the risk of ovarian cancer especially, and the other two, RAD51B and XRCC2 have been associated with breast cancer risk.
|
26351136 |
2016 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results confirm that RAD51C and RAD51D are moderate ovarian cancer susceptibility genes and suggest that they confer levels of risk of EOC that may warrant their use alongside BRCA1 and BRCA2 in routine clinical genetic testing.
|
26261251 |
2015 |
Carcinoma, Ovarian Epithelial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although the cumulative frequency of RAD51C and RAD51D truncating mutations in our patients was lower than that of the BRCA1 and BRCA2 genes, it may explain OC susceptibility in approximately 3% of high-risk OC patients.
|
26057125 |
2015 |
Carcinoma, Ovarian Epithelial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We aimed to determine the prevalence of germline RAD51D mutations in Spanish BC/OC families negative for BRCA1/BRCA2 mutations.
|
24130102 |
2014 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this current study was to validate the reported association of RAD51D with ovarian cancer and assess for an association with breast cancer.
|
23372765 |
2013 |
Carcinoma, Ovarian Epithelial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent data show that mutations in RAD51D have an aetiological role in ovarian carcinoma, yet mutations do not appear to be associated with an increased risk for breast cancer.
|
22415235 |
2012 |
Carcinoma, Ovarian Epithelial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Loss of function germline mutations in RAD51D in women with ovarian carcinoma.
|
22986143 |
2012 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results of this study on familial and unselected breast, ovarian, colorectal, and prostate cancer patients suggest that RAD51D is primarily a moderate penetrance susceptibility gene for ovarian cancer, with clinical significance for the carriers.
|
22652533 |
2012 |
Carcinoma, Ovarian Epithelial
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that RAD51D mutation testing may have clinical utility in individuals with ovarian cancer and their families.
|
21822267 |
2011 |